BETA DRUGS
Back to Balance Sheet
|
BETA DRUGS Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹445 Cr | ₹262 Cr | ₹204 Cr | ₹163 Cr | ₹120 Cr |
What is the latest Total Liabilities ratio of BETA DRUGS ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹445 Cr |
| Mar2024 | ₹262 Cr |
| Mar2023 | ₹204 Cr |
| Mar2022 | ₹163 Cr |
| Mar2021 | ₹120 Cr |
How is Total Liabilities of BETA DRUGS Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹445 Cr | 69.60 | |
| Mar2024 | ₹262 Cr | 28.69 | |
| Mar2023 | ₹204 Cr | 25.06 | |
| Mar2022 | ₹163 Cr | 35.71 | |
| Mar2021 | ₹120 Cr | - | |
Compare Total Liabilities of peers of BETA DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BETA DRUGS | ₹2,296.7 Cr | -5.3% | 41.1% | 20.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,593.0 Cr | 2% | 6.7% | 14.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,737.0 Cr | 3.5% | 2.2% | 0.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹164,290.0 Cr | 4.6% | 9.9% | 41.5% | Stock Analytics | |
| CIPLA | ₹117,327.0 Cr | -0.3% | 3.7% | -2.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,994.0 Cr | 1.1% | 5.9% | 6.6% | Stock Analytics | |
BETA DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BETA DRUGS | -5.3% |
41.1% |
20.9% |
| SENSEX | 2.2% |
5.1% |
-7% |
You may also like the below Video Courses